135 related articles for article (PubMed ID: 9681205)
21. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
22. Steroidal antiandrogens and 5alpha-reductase inhibitors.
Bratoeff E; RamÃrez E; Murillo E; Flores G; Cabeza M
Curr Med Chem; 1999 Dec; 6(12):1107-23. PubMed ID: 10519917
[TBL] [Abstract][Full Text] [Related]
23. The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate.
Wenderoth UK; George FW; Wilson JD
Endocrinology; 1983 Aug; 113(2):569-73. PubMed ID: 6872940
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
25. Consideration of the use of 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5- alpha-androstan-3-one (4MA), a 5 alpha-reductase inhibitor, in prostate cancer therapy.
Geldof AA; Meulenbroek MF; Dijkstra I; Bohlken S; Rao BR
J Cancer Res Clin Oncol; 1992; 118(1):50-5. PubMed ID: 1729259
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of action and pure antiandrogenic properties of flutamide.
Labrie F
Cancer; 1993 Dec; 72(12 Suppl):3816-27. PubMed ID: 8252497
[TBL] [Abstract][Full Text] [Related]
27. 5 Alpha-reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat.
Brooks JR; Berman C; Primka RL; Reynolds GF; Rasmusson GH
Steroids; 1986 Jan; 47(1):1-19. PubMed ID: 3810695
[TBL] [Abstract][Full Text] [Related]
28. An inhibitory effect of TZP-4238 on the growth of androgen-sensitive rat prostatic tumor (Dunning R3327).
Ichikawa T; Akimoto S; Shimazaki J
Endocr J; 1993 Aug; 40(4):425-30. PubMed ID: 7522799
[TBL] [Abstract][Full Text] [Related]
29. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
30. LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male rats.
Neubauer BL; Best KL; Blohm TR; Gates C; Goode RL; Hirsch KS; Laughlin ME; Petrow V; Smalstig EB; Stamm NB
Prostate; 1993; 23(3):181-99. PubMed ID: 8234065
[TBL] [Abstract][Full Text] [Related]
31. Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase.
Juniewicz PE; Barbolt TA; Egy MA; Frenette G; Dube JY; Tremblay RR
Prostate; 1990; 17(2):101-11. PubMed ID: 2169047
[TBL] [Abstract][Full Text] [Related]
32. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Redding TW; Schally AV
Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
[TBL] [Abstract][Full Text] [Related]
33. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
34. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs.
Juniewicz PE; Hoekstra SJ; Lemp BM; Barbolt TA; Devin JA; Gauthier E; Frenette G; Dube JY; Tremblay RR
Endocrinology; 1993 Aug; 133(2):904-13. PubMed ID: 8393778
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology and pharmacokinetics of flutamide.
Neri R
Urology; 1989 Oct; 34(4 Suppl):19-21; discussion 46-56. PubMed ID: 2477934
[TBL] [Abstract][Full Text] [Related]
36. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
Shibata Y; Ono Y; Kashiwagi B; Suzuki K; Fukabori Y; Honma S; Yamanaka H
Urology; 2003 Nov; 62(5):942-6. PubMed ID: 14624931
[TBL] [Abstract][Full Text] [Related]
37. Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Prostate; 1998 Jun; 35(4):237-42. PubMed ID: 9609545
[TBL] [Abstract][Full Text] [Related]
38. Biological activities of a new steroidal inhibitor of delta 4-5 alpha-reductase.
Brooks JR; Berman C; Hichens M; Primka RL; Reynolds GF; Rasmusson GH
Proc Soc Exp Biol Med; 1982 Jan; 169(1):67-73. PubMed ID: 7063497
[No Abstract] [Full Text] [Related]
39. Melengestrol acetate and megestrol acetate are prostatic tumor inhibiting agents.
Padilla GM; Yacullo RC; Padilla JJ; Payne B; Petrow V
Biochem Cell Biol; 1990 Oct; 68(10):1181-8. PubMed ID: 2268413
[TBL] [Abstract][Full Text] [Related]
40. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
